US OptionsDetailed Quotes
BWAY250117C7500
- 0.00
- 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-18.83%PremiumJan 17, 2025Expiry Date1.74Intrinsic Value100Multiplier26DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.85Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Brainsway Stock Discussion
BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
Thursday, 12th December at 8:00 am
BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in the advanced non-invasive treatment of brain disorders, today announced recent positive pilot data from an independent, third-party study conducted at Stanford University evalua...
BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy
BrainsWay (NASDAQ & TASE: BWAY) announced positive feasibility clinical data for their Deep TMS™ therapy in treating peripheral neuropathic pain. The double-blind, randomized crossover trial involved 17 patients who received either active Deep TMS or sham treatment for five days, followed by a nine-week washout period before switching treatments. Results demonstrated significant r...
BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada
BrainsWay has announced an exclusive multi-year distribution agreement to market its Deep Transcranial Magnetic Stimulation (Deep TMS) system in Canada. The agreement involves a specialty distributor serving acute and non-acute healthcare sectors, and includes minimum quantity orders, starting with 11 systems in 2024. BrainsWay’s CEO, Hadar Levy, emphasized the significance of exp...
BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression
BrainsWay has announced that the FDA has expanded the indication for its Deep Transcranial Magnetic Stimulation system (Deep TMS™) to treat major depressive disorder (MDD) in patients aged 22 to 86, extending beyond the previous age limit of 68. This marks the company's 10th FDA clearance, making their Deep TMS the only TMS device approved for depression treatment in patients over 68. The expanded lab...
Depression is a formidable adversary at any age, but it poses unique challenges for the elderly. Traditional treatments often fall short, leaving a gap that demands innovative solutions. Enter Deep Transcranial Magnetic Stimulation (Deep TMS) technology, a beacon of hope for those battling late-life depression. Recent findings f...
FIRST SIGNED OF MORE UPTREND: $9.37
NEED IT TO BREAK OVER: $9.54
key indicator for MORE uptrend $9.73
confirmation uptrend - $10.26
mini breakout - $10.69
full breakout - $10.91
SEMI PARABOLIC - $11.17
stop loss — $8.91
support - $8.66 $Brainsway (BWAY.US)$
No comment yet